| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| α-Bisabolol — α-Bisabolol is a naturally occurring monocyclic sesquiterpene alcohol best known as a major bioactive constituent of chamomile essential oil, especially German chamomile (Matricaria chamomilla / Matricaria recutita) and related chamomile preparations. It is a small lipophilic phytochemical classified as a plant-derived essential-oil terpene alcohol, with common abbreviations including α-BSB, BSB, and levomenol for the (-)-α-bisabolol enantiomer. In oncology research it is mainly a preclinical pro-apoptotic and anti-invasive compound with preferential mitochondrial stress effects in cancer models; in clinical deployment it remains a cosmetic/natural-health constituent rather than an approved anticancer drug. -The main components in German chamomile are terpenoid; α-bisabolol and its oxide azulenes, such as chamazulene (1–15%); and apigenin. Roman chamomile, on the other hand, contains mainly angelic acid and tiglic acid esters. Apigenin is a main bioactive component and considered a quality marker of chamomile.Primary mechanisms (ranked):
Bioavailability / PK relevance: α-Bisabolol is highly lipophilic and poorly water soluble, so systemic translation depends strongly on formulation, route, dose, and vehicle. Essential-oil or neat-compound exposure does not imply predictable plasma exposure, and advanced delivery systems such as cyclodextrin complexes, nanoemulsions, or lipid carriers may be required for reproducible systemic or CNS delivery. In-vitro vs systemic exposure relevance: Most anticancer findings use direct in-vitro exposure at micromolar to high-micromolar concentrations, often with solvent-assisted delivery. These concentrations may exceed achievable free systemic exposure after ordinary chamomile tea, dietary chamomile, or topical/cosmetic use. Chamomile oil composition is also chemotype-dependent, so α-bisabolol content can vary substantially. Clinical evidence status: Cancer evidence is preclinical only. There are human trials of α-bisabolol-containing topical products for non-cancer indications, and chamomile has natural-health/traditional-use monographs for digestive, inflammatory gastrointestinal, and calmative uses, but there is no established human oncology indication, no approved anticancer label, and no cancer RCT evidence for α-bisabolol or chamomile oil. Mechanistic Profile
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr Alzheimer’s disease relevance: α-Bisabolol has meaningful preclinical AD relevance through amyloid-β toxicity reduction, mitochondrial protection, anti-inflammatory activity, oxidative-stress reduction, and possible cholinesterase-related effects. Evidence includes Aβ-induced cell and animal/C. elegans models, scopolamine-memory models for α-bisabolol derivatives, and chamomile essential-oil studies with α-bisabolol-rich composition. However, there is no established human AD clinical evidence for α-bisabolol, and brain exposure is likely formulation-dependent because the compound is lipophilic and poorly water soluble. |
| Source: |
| Type: |
| Protein expression of ATF, GRP78, and GADD153 which is a hall marker of ER stress. The endoplasmic reticulum (ER) stress signaling pathway plays a crucial role in maintaining cellular homeostasis and responding to various stressors, including those encountered in cancer. When cells experience stress, such as the accumulation of misfolded proteins, they activate a series of signaling pathways collectively known as the unfolded protein response (UPR). The UPR aims to restore normal function by enhancing the protein-folding capacity of the ER, degrading misfolded proteins, and, if the stress is unresolved, triggering apoptosis. The activation of ER stress pathways can contribute to resistance against chemotherapy and targeted therapies. Cancer cells may utilize the UPR to survive treatment-induced stress, making it challenging to achieve effective therapeutic outcomes. -ER stress-associated proteins include: phosphorylation of PERK, eIF2α, ATF4, CHOP and cleaved-caspase 12 |
| - | in-vivo, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:413 Target#:103 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid